Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
21/08/2026 02:55
BRIEF-Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China Aug 21 (Reuters) - CStone Pharmaceuticals 2616.HK:
RECEIVES NMPA IND APPROVAL FOR CS5007 IN CHINA
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026